Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-22
2007-05-22
Davis, Zinna N. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S141000
Reexamination Certificate
active
10836377
ABSTRACT:
The present invention relates to an isoquinoline compound represented by the following formula (I), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct thereof, a hydrate thereof and a solvate thereof, as well as an agent for the prophylaxis and/or treatment of a disease caused by hyperreactivity of poly(ADP-ribose)polymerase, containing the compound, and a poly(ADP-ribose)polymerase inhibitor containing the compound. In addition, this compound is useful as an agent for the prophylaxis and/or treatment of cerebral infarction, particularly as an agent for the prophylaxis and/or treatment of acute cerebral infarction. Furthermore, this compound is useful as a prophylactic and/or therapeutic agent that improves neurological symptoms associated with cerebral infarction, particularly acute cerebral infarction.wherein the symbols are the same as defined in the description.
REFERENCES:
patent: 4113731 (1978-09-01), Winters et al.
patent: 4808595 (1989-02-01), Hoffman, Jr.
patent: 2004/0176361 (2004-09-01), Fujio et al.
patent: 2 371 174 (2000-11-01), None
patent: 2 371 645 (2000-11-01), None
patent: 2 372 704 (2000-11-01), None
patent: 2 121 031 (1972-11-01), None
patent: 0 355 750 (1990-02-01), None
patent: 1 142 881 (2001-10-01), None
patent: 1 148 053 (2001-10-01), None
patent: 1 396 488 (2004-03-01), None
patent: 1062357 (1967-03-01), None
patent: 1174272 (1969-12-01), None
patent: 46-12454 (1971-03-01), None
patent: 52-156875 (1977-12-01), None
patent: 54-84597 (1979-07-01), None
patent: 64-42472 (1989-02-01), None
patent: 02-124874 (1990-05-01), None
patent: WO 99/08680 (1999-02-01), None
patent: WO 99/11624 (1999-03-01), None
patent: WO 99/11628 (1999-03-01), None
patent: WO 99/11645 (1999-03-01), None
patent: WO 99/11649 (1999-03-01), None
patent: WO 99/59973 (1999-11-01), None
patent: WO 00/42025 (2000-07-01), None
patent: WO 00/44726 (2000-08-01), None
patent: WO 00/64878 (2000-11-01), None
patent: WO 00/67734 (2000-11-01), None
patent: WO 00/68206 (2000-11-01), None
patent: WO 01/79184 (2001-10-01), None
patent: WO 02/44157 (2002-06-01), None
patent: WO 02/48117 (2002-06-01), None
patent: WO 02/090334 (2002-11-01), None
patent: WO 02/94790 (2002-11-01), None
patent: WO 03/063874 (2003-08-01), None
patent: WO 2004/048339 (2004-06-01), None
Ohta et al.Chem Pharm.Bull., 41(6), pp. 1188-1190 (1993).
Eliasson et al.Nature Medicine, 3(10), pp. 1089-1095 (1997).
Kimoto et al.,Yakugaku Zasshi, 91(12): 1279-1285 (1971).
Tomisawa et al.,Chem. Pharm. Bull, 19(11): 2414-2417 (1971).
Egi Yasuhiro
Fujio Masakazu
Inoue Shinya
Matsumoto Toshifumi
Satoh Hiroyuki
Leydig , Voit & Mayer, Ltd.
Mitsubishi Pharma Corporation
LandOfFree
Isoquinoline compound and pharmaceutical use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isoquinoline compound and pharmaceutical use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isoquinoline compound and pharmaceutical use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3758097